Advances in DNA Repair in Cancer Therapy [electronic resource] / edited by Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali.

Preface -- Repair of DNA Interstrand Cross-links Produced by Cancer Chemotherapeutic Drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy? -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- The relationship between DNA-repair genes, cellular radiosensitivity and the response of tumors and normal tissues to radiotherapy -- Important Roles of ERCC1 in DNA Repair and Targeted Therapy -- The role of BRCA1 and BRCA2 in anticancer drug therapy -- DNA-PK in CLL Chemotherapy -- Poly(ADP) ribose polymerase at the interface of DNA damage signalling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a Therapeutic Target -- Telomeres, Telomerase and DNA Damage Response in Cancer Therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index.

This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling is examined.

ZDB-2-SME